Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial-Reference-Cited by-同舟云学术

Pharmacokinetics, safety, and efficacy of subcutaneous versus intravenous rituximab plus chemotherapy as treatment for chronic lymphocytic leukaemia (SAWYER): a phase 1b, open-label, randomised controlled non-inferiority trial

Published:2016-03 Issue:3 Volume:3 Page:e128-e138
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Assouline Sarit,Buccheri Valeria,Delmer Alain,Gaidano Gianluca,Trneny Marek,Berthillon Natalia,Brewster Michael,Catalani Olivier,Li Sai,McIntyre Christine,Sayyed Pakeeza,Badoux Xavier

Publisher

Elsevier BV

Subject

Hematology

Reference27 articles.

1. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial;Hallek;Lancet,2010

2. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group;Stilgenbauer;J Clin Oncol,2009

3. Preference for subcutaneous or intravenous administration of trastuzumab in patients with HER2-positive early breast cancer (PrefHer): an open-label randomised study;Pivot;Lancet Oncol,2013

4. Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom;Rule;J Med Econ,2014

5. Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study;Davies;Lancet Oncol,2014

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacology Approaches to Support Approval of New Routes of Administration for Therapeutic Proteins;Clinical Pharmacology & Therapeutics;2024-01-18

3. The comparison of safety and cost between reference drug of rituximab and its biosimilar Riximyo in lymphoproliferative disorders and other hematological diseases. Single center experience;Leukemia & Lymphoma;2023-10-27

4. Infective complications in cancer patients treated with subcutaneous versus intravenous trastuzumab and rituximab: An individual patient data meta-analysis;Journal of Oncology Pharmacy Practice;2023-06-16

5. Acalabrutinib and high-frequency low-dose subcutaneous rituximab for initial therapy of chronic lymphocytic leukemia;Blood Advances;2023-06-02